New Treatments & Clinical Trials for Beta Thalassemia

Beta thalassemia is an inherited blood disorder where the body makes too little hemoglobin, causing anemia that ranges from mild to severe. People with the most severe form, transfusion-dependent beta thalassemia, need regular blood transfusions for life. Treatment has long focused on managing anemia and iron overload from transfusions, but gene therapy and newer drugs are changing what's possible.

What's actually going on in research

Trials are testing gene therapies that modify a patient's own stem cells to produce healthy hemoglobin, sometimes achieving transfusion independence. Luspatercept, approved by FDA in 2019, reduces transfusion needs in some adults. Research also includes gene editing with CRISPR, drugs that increase fetal hemoglobin production, and treatments aimed at iron overload and bone disease complications.

What to know before you search

Eligibility typically depends on transfusion frequency, disease severity, iron levels, age, and whether someone has had previous stem cell transplant or gene therapy.

What types of trials are currently open

• Gene therapy trials — Testing one-time treatments where a patient's stem cells are removed, modified to produce healthy hemoglobin, and returned. These often require chemotherapy to prepare the bone marrow.
• Gene editing trials — Studies using CRISPR or similar technologies to edit genes in stem cells, usually aiming to increase fetal hemoglobin production.
• Drug trials — Testing medications that reduce transfusion needs, often by increasing fetal hemoglobin or improving how red blood cells mature.
• Iron chelation trials — Testing new ways to remove excess iron that builds up from repeated transfusions, which can damage organs if not managed.
• Natural history studies — Following people with beta thalassemia over time to understand disease progression, complications, and how well current treatments work in real-world settings.